Company news
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) news
Acrivon Therapeutics, Inc. news releases on 6ix. Latest, Nov 28, 2023: Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation…
Press releases — page 2
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
November 27, 2023
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
November 20, 2023
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 8, 2023
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2023
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference ...
September 18, 2023
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
September 4, 2023
Acrivon Therapeutics to Participate in Two Investor Conferences in September
August 29, 2023
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 10, 2023
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
July 19, 2023
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
June 21, 2023
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference
June 1, 2023
Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 8, 2023
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
May 8, 2023
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
April 24, 2023
Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023
April 23, 2023
Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference
April 17, 2023
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 27, 2023
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 5, 2023
Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care Conference
February 26, 2023